Secondary malignant neoplasm of other and unspecified sites
Chapter 2:Neoplasms
ICD-10 C79 is a billable code used to indicate a diagnosis of secondary malignant neoplasm of other and unspecified sites.
C79 refers to secondary malignant neoplasms that arise from a primary cancer located in another organ or tissue. These neoplasms can occur in various sites, including but not limited to the liver, lungs, bones, and brain. The term 'secondary' indicates that the cancer has metastasized from its original site, which may not always be identifiable. In cases where the primary site is unknown, the neoplasm is classified under C79. This code encompasses a wide range of metastatic diseases, highlighting the complexity of cancer staging and treatment. Accurate coding is essential for effective patient management, including staging, treatment planning, and palliative care considerations. Palliative care focuses on improving the quality of life for patients with advanced cancer, emphasizing symptom management and psychosocial support. The coding of secondary malignant neoplasms requires careful documentation of the patient's history, the extent of disease, and any treatments received, as these factors influence both clinical management and reimbursement.
Detailed history of the primary cancer, treatment history, and current status of metastatic disease.
Patients presenting with new symptoms related to known metastatic disease.
Ensure that all sites of metastasis are documented and coded accurately.
Comprehensive assessment of symptoms, treatment goals, and patient preferences.
Patients requiring symptom management for advanced metastatic cancer.
Focus on quality of life and symptom relief, with clear documentation of palliative interventions.
Used for follow-up visits for patients with metastatic disease.
Document the patient's history, examination findings, and treatment plan.
Oncology specialists should ensure that the visit reflects the complexity of managing metastatic disease.
C79 is used for secondary malignant neoplasms with a known or unknown primary site, while C80 is for unspecified malignant neoplasms without a defined primary site.
